Pubblicazioni

Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours. CLARINET FORTE phase 2 study results

2021 - EUROPEAN JOURNAL OF CANCER

Pavel, M.; Cwikla, J. B.; Lombard-Bohas, C.; Borbath, I.; Shah, T.; Pape, U. F.; Capdevila, J.; Panzuto, F.; Truong Thanh, X. -M.; Houchard, A.; Ruszniewski, P.